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Escapeoteins to target by vaccination in order to generate the most effective CD8 T-cell
immunity. We recently immunized SIVmac251-infected pigtail macaques with Gag peptides or a cocktail of
peptides spanning all SIV proteins, including SIV Env. High-level SIV Env-speciﬁc CD8 T-cell responses were
generated and 7 novel Env-speciﬁc CD8 T-cell epitopes in 10 animals were mapped. Env-speciﬁc CD8 T-cell
responses were signiﬁcantly inferior to Gag-speciﬁc responses, and no better than unvaccinated control
animals, in the control of SIV replication and prevention of disease. Escape mutations emerged within several
Env-speciﬁc CTL epitopes, suggesting at least some pressure imparted by the Env CTL responses, but this did
not correlate with signiﬁcantly reduced SIV replication. We conclude Env-speciﬁc CTL may not be the most
effective response to induce by vaccination.
© 2008 Elsevier Inc. All rights reserved.IntroductionStructural proteins appeal as CD8 T-cell vaccine targets due to their
potentially more conserved genome and tighter restraint onmutation,
ostensibly to maintain structure and function. Gag is a frequent
component of HIV vaccine candidates progressing through clinical
trials and Env is frequently included to broaden T-cell immunity and
induce antibody responses (Catanzaro et al., 2007).
Gag-speciﬁc T-cell immunity has been the focus of several recent
human and macaque studies. Broad Gag-speciﬁc CD8 T-cell responses
have been shown to correlate with reduced viremia compared to other
HIV-1 antigens including Env in humans (Kiepiela et al., 2007;
Masemola et al., 2004). Gag is presented and available for CTL-
mediated killing of SIV-infected PBMCs much earlier in the viral life
cycle than Env (Sacha et al., 2007). Compelling studies have shown
that immune escape mutations in Gag commonly result in impaired
viral ﬁtness in both human studies of acute and chronic HIV-1
infection (Allen et al., 2005; Fernandez et al., 2005; Friedrich et al.,
2004; Leslie et al., 2004), and in SHIV/SIV-infected macaques (Allen et
al., 2005; Fernandez et al., 2005; Friedrich et al., 2004; Leslie et al.,
2004).
Env, however, is the only HIV protein targeted by both the cell-
mediated and neutralizing antibody (NAb) responses. Should Env
require multiple mutations to evade both CTL and NAb, we
speculated that the resultant ﬁtness cost to the virus may slow
progression to disease and limit transmission (Peut and Kent, 2007).
Several macaque vaccine studies have suggested vaccines expressingl rights reserved.multiple proteins, including Env, contribute to enhanced control of
chimeric SHIV strains; however, these studies may be confounded
by induction of NAb to the closely homologous challenge virus
(Amara et al., 2002; Polacino et al., 1999). We recently reported that
HIV-1 Env-speciﬁc CD8 T-cell responses were not effective in
controlling SHIV challenge after vaccination that could not induce
NAb (Peut and Kent, 2007). However, that study elicited only low
levels of Env-speciﬁc CTL, the vaccination and challenge Env strains
were from different subtypes, and the challenge SHIV was a CXCR-4
utilizing strain, rapidly depleting CD4 T-cells. The X4–SHIV systems
do not accurately model human infection with CCR5-tropic HIV-1,
the most frequently transmitted strains. The role of high levels of
Env-speciﬁc CD8 T-cells in controlling a CCR5-utilizing non-human
primate lentivirus requires further study.
We recently reported a therapeutic vaccine study of overlapping
SIV peptides in pigtail macaques previously infected with the R5-
tropic SIVmac251 (De Rose et al., 2008). The immunizations induced
high levels of SIV-speciﬁc T-cells without inducing antibodies. This
study presented an ideal opportunity to prospectively identify and
map SIV Env-speciﬁc CD8 T-cell responses, and then compare the
impact of Env- and Gag-speciﬁc CD8 T-cell responses upon the
outcome of an R5-SIV infection.
Results
SIV Env CTL responses
To investigate Env- and Gag-speciﬁc CD8 T-cell immunity in
controlling a CCR5-utilizing virus, CTL responses were tracked in all 32
SIVmac251-infected pigtail macaques participating in a peptide-based
22 Rapid Communicationtherapeutic vaccine study (De Rose et al., 2007). The vaccine strategy
involved using Overlapping Peptide-pulsed Autologous peripheral
blood celLs (termed OPAL).Wemeasured the proportion of CD8 T-cells
speciﬁcally expressing intracellular IFNγ in response to stimulation
with SIV peptide pools. Substantial T-cell immunity was induced to
the relevant antigens across the vaccine groups, with mean Gag-
speciﬁc CD8 T-cells of 1.58% in the OPAL-Gag group and 0.37% in the
OPAL-All group, 2 weeks after the last vaccination. At this same time
point, mean Env-speciﬁc responses in the OPAL-Gag and OPAL-All
group were 0.15% and 11.76% respectively (Table 1). After the
antiretrovirals were withdrawn at week 10, there was an overall 10-
fold reduction in plasma SIV viral load (VL) in both treatment groups
compared to unimmunized controls during the 1 year follow up (De
Rose et al., 2008).
To determine the utility of Env-speciﬁc CTLs, we undertook an
extensive process of identifying, conﬁrming and mapping Env-
speciﬁc CD8 T-cell responses. Antigen-speciﬁc CD8 T-cells releasing
IFNγ were quantiﬁed by intracellular cytokine staining (ICS) as
previously described (Dale et al., 2004), using 15mer SIV peptides
overlapping by 11 amino acids (kindly supplied by the NIH AIDS
reagent repository). Responses were mapped to individual 15mers
and minimal CD8 T-cell epitopes were identiﬁed using ICS titration
assays of candidate peptides as shown in Fig. 1 (Peut and Kent,
2007). Seven Env-speciﬁc CD8 T-cell epitopes were identiﬁed in 10
animals. Three epitopes, HF8226–233, SL10524–533 and DL9679–687 were
identiﬁed in multiple animals (Table 1). The 3 animals recognisingTable 1
Env and Gag CD8 T-cell immunity
Vaccine
regime
n Animal
no.
Mane-Aa10
status
Week 12d %
CD8 Env respa
Week 12 %
CD8 Gag respa
Controls 11 6169 Neg 0.00 0.79
7992 Neg 0.05 0.26
8014 Pos 0.09 0.12
8252 Neg 0.00 0.00
8436 Neg 0.03 0.00
8868 Neg 0.14 0.48
8883 Neg 0.00 0.03
9017 Pos 0.00 0.97
9019 Neg 0.08 0.03
9176 Pos 0.00 0.11
9183 Pos 0.03 0.39
MEAN 0.04 0.29
OPAL-Gag 10 9196 Neg 3.12 0.94
6597 Neg 0.44 2.73
8012 Neg 0.30 1.00
6804 Neg 0.00 1.36
8020 Pos 0.00 4.00
8241 Pos 0.10 0.35
8244 Pos 0.09 0.29
8454 Pos 0.08 2.59
8673 Neg 0.10 0.79
8873 Neg b0.32 1.71
MEAN 0.15 1.58
OPAL-All 11 8676 Neg 54.20 0.13
8682 Neg 50.11 0.04
8247 Neg 12.57 0.05
2.3308 Neg 5.46 0.18
8680 Neg 3.92 0.05
8251 Neg 1.76 0.16
8240 Pos 0.48 1.05
9020 Pos 0.07 0.38
9021 Pos b0.29 1.21
9175 Pos c0.18 0.17
1.3731 Pos b0.28 0.66
MEAN 11.76 0.37
a CD8 T-cell responses b0.20% were too low to sustain the ﬁne mapping procedure or to
b Exceptions were 8873,1.3731 and 9021 when the Env-speciﬁc responses dropped drama
mapping procedure and
c 9175, whose Gag-speciﬁc CD8 T-cell response more than doubled to 0.39% at week 14 p
d Week 12 post infection was 2 weeks after last vaccination.the epitope SL10 had remarkably strong peak responses of 12–54%
of all CD8 T-cells at week 12 post infection. The substantial Env-
speciﬁc CD8 T-cell response in animal 8676 is illustrated in Figs. 1A–
D, where very high levels of CD8 T-cells responding to the pool of
25 15mer Env peptides numbered 125–149 at week 14 post
infection and mapped to a single 15mer peptide 131 (containing
the SL10 10mer epitope) at week 16 post infection.
Role of Env CTL in controlling SIV
We then assessed the role of Env-speciﬁc CD8 T-cell responses in
controlling SIV replication. We ﬁrst compared VL and peripheral
CD4 levels in Env and Gag CTL responders, since Gag-speciﬁc
cellular immunity has been clearly linked to improved outcomes
(Kiepiela et al., 2007). Our analysis was conducted on animals
within the vaccine groups to assess the effect of enhancing Env- or
Gag-speciﬁc T-cells by therapeutic immunization. Our primary
analysis excluded Mane-A⁎10 positive animals, given these animals
all mount a dominant Gag-speciﬁc CTL responses to the KP9 epitope
associated with improved control of SIV (Fernandez et al., 2005,
2007; Smith et al., 2005a). Interestingly, the VL of the Env non-
responders including the A⁎10 animals is slightly higher (0.57 log10
copies/mL) than the VL of the Env non-responders excluding the
A⁎10 animals (Supplementary Table 1), perhaps reﬂecting immune
escape at the dominant Gag KP9 epitope (data not shown) being
detrimental as recently described (Fernandez et al., 2007). OurWeek 12 VL (ART
ceased wk 10)
Euthanised
week #
Mapped Env
epitope
Location on Env
protein (aa #)
3.94
5.58 44
4.55
5.43 48
4.72 46
4.72 46
5.24 46
3.91
4.62 46
3.94
3.43
4.55
3.76 HYWDTIRF (HF8) 226–233 (C2)
4.26 44 DVFGNWFDL (DL9) 679–687 (gp41)
5.07 43 HYWDTIRF (HF8) 226–233 (C2)
4.97
5.12
5.55 44
3.83
3.67
4.67
4.32
4.06
5.43 44 SRNKRGVFVL (SL10) 524–533 (C5)
4.11 SRNKRGVFVL (SL10) 524–533 (C5)
5.59 41 VLPVTIMSGLV (VV11) 322–335 (C2)
SRNKRGVFVL (SL10) 524–533 (C5)
4.78 44 SRVYQILQP (SP9) 795–803 (gp41)
3.80 TMSAEVAELY (TY10) 484–493 (C5)
4.66 MNWFLNWVED (MD10) 407–416 (V4)
3.11 DVFGNWFDL (DL9) 679–687 (gp41)
3.11
3.82
3.50
4.48
3.86
be considered to have an antigen-speciﬁc response.
tically to 0.06%, 0.13% and 0.09% at week 14 post infection, precluding them from the ﬁne
ost infection and was then classiﬁed as having a positive response.
Fig. 1. Identifying minimal Env CD8 T-cell epitopes. Large Env-speciﬁc CD8 T-cell responses were mapped to individual minimal epitopes. Panels A–D illustrate FACS plots of control
responses (A, C) and Env-speciﬁc responses (B, D) in 2 macaques. (A) Shows a FACS plot of a negative response to a non-responding Env peptide pool by animal 8676 at week 14 post
infection. (B) 51% of all CD8 T-cells react to the peptide pool containing 25 15mer Env peptides numbered 125–149 for animal 8676 at week 14 post infection. (C) Negative control
DMSO for animal 8676 atweek 16 post infection. (D) 35% of all CD8 T-cells react to the single 15mer peptide number 131 at 16weeks post infection. (E) To identifyminimal SIV Env CD8
T-cell epitopes, ICS assays were performed on freshwhole bloodwith titration curves to ascertain the smallest candidate peptide that elicited the largest or equal largest proportion of
CD8 T-cells expressing IFNγ down a concentration gradient. Examples of 3 epitopes are shown —with the minimal epitopes being SL10, HF8 and DL9 (bold lines with open circles).
23Rapid Communicationresults should however be interpreted cautiously given the limited
numbers in each sample.
Env-only CTL responders maintained a signiﬁcantly higher
average VL between weeks 12–64 post infection than did animals
with Gag-only CD8 T-cell responses excluding the Mane-A⁎10+
animals (5.05±0.38 log10 copies/mL versus 3.65±0.24 log10 copies/
mL respectively. P=0.039, Fig. 2A). The average VL of the 6 Env-only
responders was similar to the 7 Mane-A⁎10 negative, unvaccinated,
controls (5.05±0.38 log10 copies/mL and 5.49±0.35 log10 copies/mL
respectively. P=0.445, Fig. 2A).
To address speculation that a broad, multi-protein response could
be beneﬁcial, those animals with CD8 T-cell responses to both Env andGagwere then included in this analysis. VL for the 3 animals with both
Env- and Gag-speciﬁc responses averaged 5.01±0.56 log10 copies/mL
between weeks 12–64 post infection. This was signiﬁcantly higher
than the Gag-only responders (P=0.049) and no better than the Env-
only response.
For completeness, the 9 Mane-A⁎10 positive animals in the
vaccinated groups were then included and characterised on the
basis of having an Env-speciﬁc CTL response or not (Supplementary
Table 1). Eight of these Mane-A⁎10 positive animals had no Env
response and 1Mane-A⁎10 positive animal had both an Env and a Gag
response. A similar trend was observed where having an Env-only or
an Env- and Gag-speciﬁc response is no more beneﬁcial for viremic
Fig. 2. CD8 T-Cell Env responders versus Gag responders. Six Env-only responders, 3 Gag-only responders, 3 animals with both Env- and Gag-speciﬁc CD8 T-cell responses and 7
unvaccinated controls were studied for – (A) Viral load. ART treatment of tenofovir (TDF) and emtricitabine (FTC) was given from weeks 3 to 10 (gray block) – daily from weeks
3–5 and 3 times per week from weeks 6–10. The OPAL vaccination therapy was given as single applications at weeks 4, 6, 8 and 10 post infection (black arrows). A further OPAL
boost was given at weeks 36, 39 and 42. (B) Peripheral CD4 T-cell levels. (C) Survival graph showing 2 of 6 Env-only responders euthanised by week 44, 0 of 3 Gag responders
euthanised by week 64, 2 of 3 animals with both Env- and Gag-speciﬁc responses euthanised by week 44 and 7 of 11 control animals euthanised by week 64 post infection. No
Mane-A⁎10 positive animals included. A last observation carried forward analysis was used for VL and CD4 T-cell counts where animals were euthanised prior to week 64.
24 Rapid Communicationcontrol than having no Env-speciﬁc response, and is signiﬁcantly
inferior to having a Gag-only response.
We followed the animals in this trial for just over 1 year after
the last vaccination and removal of ART. This enabled an analysis of
survival in animals responding to Env or Gag. During follow up, a
total of 6 vaccinated animals and 6 controls of the 32 animals were
euthanised with incipient AIDS, including weight loss, CD4 T-cell
depletion and thrombocytopenia (De Rose et al., 2008). Animals
responding to Env-only CD8 T-cell epitopes progressed to AIDS
more frequently than animals with CTL responses to Gag alone
(Fig. 2C).Immune escape at SIV Env CTLs
One characteristic of an effective CTL response is its ability to force
viral mutation. To identifymutationswithin Env-speciﬁc CTL epitopes,
we sequenced multiple viral clones from plasma SIV RNA at several
time-points as described (Peut and Kent, 2007) using SIV Env primers
and PCR conditions shown in Supplementary Table 2. Viral mutation
was identiﬁed in the 3 common Env CTL epitopes (HF8, SP9 and SL10)
in 5 animals (Supplementary Table 3). The timing and rates of
mutations within the CTL epitopes varied markedly (Fig. 3A). The
dominant mutations within SL10 epitope, N526D and N526T, were
Fig. 3.Mutations within Env-speciﬁc CD8 T-cell epitopes. (A) Mutation occurred in 5 animals, representing 3 Env-speciﬁc CD8 T-cell epitopes (bracketed). (B) Comparison of average
VL between animals with mutated virus at the identiﬁed CD8 T-cell epitope, and those without mutation.
25Rapid Communicationindeed immune escape mutations, with 42.92% of CD8 T-cells
responding to the wildtype SL10 peptide, but only 0.04% and 0.01% of
CD8 T-cells speciﬁc to the mutants N526D and N526T SL10 peptides
respectively. No single, common, dominant mutational motif arose in
the same SIV Env-speciﬁc CD8 T-cell epitope in different animals
(Supplementary Table 3), similar to our observations in immune
escape from HIV-1 Env CTL epitopes in macaques (Peut and Kent,
2007). Therewas a non-signiﬁcantly lower average VL in the 6 animals
that exhibited no viral mutation at their Env-speciﬁc CD8 T-cell
epitopes to week 42 post infection (including oneMane-A⁎10 animal),
compared to the 5 animals that exhibited viral mutation within their
deﬁned epitopes (4.29±0.39 log10 copies/mL and 5.07±0.36 log10
copies/mL respectively P=0.428, Fig. 3B).
Discussion
In summary, this SIVmac251-macaque study highlights three con-
cerns regarding the utility of Env as a CD8 T-cell vaccine target. First,
the SIV Env-speciﬁc CD8 T-cell responses identiﬁed were unable to
signiﬁcantly impact viral replication or disease progression. Second,
Env responses may potentially inhibit more effective CD8 T-cell
responses, highlighted by the observation that a Gag-speciﬁc CTL
response correlated with better control of SIV replication, yet animals
with both Env- and Gag-speciﬁc CD8 T-cell responses fared no better
than Env-only responders or unvaccinated controls. Third, there was
no discernable effect of SIV Env-speciﬁc CD8 T-cell responses forcing
common escapemutations, potentially indicatingminimal constraints
on mutation and implying that there may be modest ﬁtness costs of
escape from Env CTL responses.
Despite the large size of this randomized SIV-macaque study, several
limitations are apparent. CD8 T-cell responses to SIV antigens other thanEnv or Gag were low, variable and of limited frequency. Mean Pol and
combined regulatory protein-speciﬁcCD8 responseswere 0.3%and2.4%,
respectively, in theOPAL-All group compared to≤0.4% for CD8 responses
to non-Gag antigens in control and OPAL-Gag groups. Their potential
effectonVL andperipheralCD4 levels are likely to be important (Kiepiela
et al., 2007). Further, lowanimal numbers in some responder groups (3–
6) reduced the robustness of the ﬁndings, particularly whenMane-A⁎10
positive animals were excluded to remove a pro-Gag bias. Having now
identiﬁed common Env-speciﬁc CTL epitopes in pigtail macaques, we
can begin to MHC-restrict the responses, develop MHC tetramers to
more sensitively detect responses and randomize future studies based
on the ability to respond to these epitopes. Anadditional limitation is the
study of only IFNγ expression as amarker of the functionality of the SIV-
speciﬁc CTLs. It is becoming clearer that expression of multiple effector
molecules as well as in vitro killing function of CTLs are likely more
accurate measures of CTL effectiveness (Betts et al., 2006; Sacha et al.,
2007) and future studies should assess a wider variety of functions of
Env-speciﬁc CTLs.
SIV Env is a potent stimulant to the cell-mediated immune system.
Unfortunately, the resultant CD8 T-cell responsewas of limited value in
controlling SIV replication or preventing SIV disease. Our results are
consistent with human observational cohorts (Kiepiela et al., 2007)
and our previouswork onHIV-1 Env CTL responses inmacaque vaccine
studies (Peut and Kent, 2007). Worse, large Env CTL responses may
hinder other subdominant protein-speciﬁc CD8 T-cell responses more
adept at restraining viral growth (Frahm et al., 2006; Friedrich et al.,
2007). The large Env responses identiﬁed in 3 animals correlated with
poor non-Env responses and very poor outcomes for the animals.
Although theremay be Env epitopes that are indeed useful, to date our
data suggest that Env-speciﬁc CD8 T-cell responses are comparatively
ineffective.
26 Rapid CommunicationMaterials and methods
Animals and vaccinations
The animals analyzed were part of a recently reported vaccination
study (De Rose et al., 2008). In brief, the study involved 36 macaques
injected intravenouslywith 40 TCID50 of SIVmac251 directly as supplied by
Dr R. Pal (Pal et al., 2002) as previously described (Batten et al., 2006;
Smith et al., 2005a). Themacaques were randomized into 3 groups of 12
animals, stratiﬁed for peak SIV viral load at week 2, weight, gender and
the MHC I geneMane-A⁎10 (known to enhance immune control of SIV
(Pratt et al., 2006; Smith et al., 2005b)). Animals received subcutaneous
injections of dual anti-retroviral therapy (ART) with tenofovir and
emtricitibine (Gilead; both 30 mg/kg/animal) for 7 weeks from week 3
(Hel et al., 2000; Lisziewicz et al., 2005; Lori et al., 2000; Shen et al., 2003;
Villinger et al., 2002). Four animals developed lethal, acute SIV infection
prior to the ﬁrst immunization with diarrhoea and rapid weight loss,
leaving 32 animals remaining in the trial (Table 1). The two vaccine
groups were immunized with PBMC pulsed with either a pool of 125
SIVmac239 Gag peptides or 823 peptides spanning all 9 SIVmac239 proteins
at 10 μg/ml of each peptide within the pool (De Rose et al., 2008). The
peptide-pulsedPBMCwereheld for 1hat37°Cand then reinfused IV into
the autologous animal. The ﬁrst 4 immunizations were administered
while themacaqueswere onARTatweeks 4, 6, 8 and 10 after infection. A
second set of immunizations was undertaken at weeks 36, 39 and 42
without ART cover. Control macaques did not receive vaccine treatment.
Immunologic and virologic evaluations
T-cell immunitywas studied by IFNγ intracellular cytokine staining
(ICS) as previously described (Peut and Kent, 2007). Brieﬂy, fresh blood
samples (200 μl) were stimulated with overlapping SIV peptide pools
for 6 h then the red cells lysed, and the remaining cells ﬁxed and
permeabilized. Cells were stained with antibodies to CD3, CD4, CD8
and IFNγ as previously described. Gated CD4+ or CD8+ T lymphocytes
expressing IFNγ were analyzed by ﬂow cytometry. To identify
individual Env epitopesweperformed the IFNγ ICS assay progressively
smaller peptide pools and then purchased minimal using peptide
epitopes and performed titration series as shown in Fig. 1 (Peut and
Kent, 2007).
SIV viral load in plasma and CD4 T-cell depletionwas monitored as
previously described (De Rose et al., 2008). To analyze viral escape at
Env CD8 T-cell epitopes, we cloned and sequenced plasma SIV RNA
from animals responding at Env epitopes at multiple times during the
course of infection as previously described (Peut and Kent, 2007). SIV
Env primers and PCR conditions are shown in Supplementary Table 2.
Differences in SIV viral load between groups of animals used a time-
weighted area under the curve analysis as previously described (Peut
and Kent, 2007).
Acknowledgments
We thank R De Rose, C Fernandez, R Mason, L Loh, S Alcantara, and
R Goli for helpful advice and assistance.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2008.11.030.
References
Allen, T.M., Altfeld, M., Geer, S.C., Kalife, E.T., Moore, C., O'Sullivan, K.M., Desouza, I.,
Feeney, M.E., Eldridge, R.L., Maier, E.L., Kaufmann, D.E., Lahaie, M.P., Reyor, L., Tanzi,
G., Johnston,M.N., Brander, C., Draenert, R., Rockstroh, J.K., Jessen, H., Rosenberg, E.S.,
Mallal, S.A., Walker, B.D., 2005. Selective escape from CD8+ T-cell responses
represents a major driving force of human immunodeﬁciency virus type 1 (HIV-1)sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79 (21),
13239–13249.
Amara, R.R., Smith, J.M., Staprans, S.I., Monteﬁori, D.C., Villinger, F., Altman, J.D., O'Neil,
S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., McNicholl, J.M., McClure,
H.M., Moss, B., Robinson, H.L., 2002. Critical role for Env as well as Gag–Pol in
control of a simian–human immunodeﬁciency virus 89.6P challenge by a DNA
prime/recombinant modiﬁed vaccinia virus Ankara vaccine. J. Virol. 76 (12),
6138–6146.
Batten, C.J., Rose, R.D., Wilson, K.M., Agy, M.B., Chea, S., Stratov, I., Monteﬁori, D.C., Kent,
S.J., 2006. Comparative evaluation of simian, simian–human, and human
immunodeﬁciency virus infections in the pigtail macaque (Macaca nemestrina)
model. AIDS Res. Hum. Retroviruses 22 (6), 580–588.
Betts, M.R., Nason, M.C., West, S.M., De Rosa, S.C., Migueles, S.A., Abraham, J., Lederman,
M.M., Benito, J.M., Goepfert, P.A., Connors, M., Roederer, M., Koup, R.A., 2006. HIV
nonprogressors preferentially maintain highly functional HIV-speciﬁc CD8+ T-cells.
Blood 107 (12), 4781–4789.
Catanzaro, A.T., Roederer,M., Koup, R.A., Bailer, R.T., Enama,M.E., Nason,M.C.,Martin, J.E.,
Rucker, S., Andrews, C.A., Gomez, P.L., Mascola, J.R., Nabel, G.J., Graham, B.S., 2007.
Phase I clinical evaluation of a six-plasmidmulticlade HIV-1 DNA candidate vaccine.
Vaccine 25 (20), 4085–4092.
Dale, C.J., De Rose, R., Stratov, I., Chea, S., Monteﬁori, D., Thomson, S.A., Ramshaw, I.A.,
Coupar, B.E., Boyle, D.B., Law, M., Kent, S.J., 2004. Efﬁcacy of DNA and fowlpoxvirus
prime/boost vaccines for simian/human immunodeﬁciency virus. J. Virol. 78,
13819–13828.
De Rose, R., Batten, C.J., Smith, M.Z., Fernandez, C.S., Peut, V., Thomson, S., Ramshaw, I.A.,
Coupar, B.E., Boyle, D.B., Venturi, V., Davenport, M.P., Kent, S.J., 2007. Comparative
efﬁcacy of subtype AE simian–human immunodeﬁciency virus priming and
boosting vaccines in pigtail macaques. J. Virol. 81 (1), 292–300.
De Rose, R., Fernandez, C.S., Smith, M.Z., Batten, C.J., Alcantara, S., Peut, V., Rollman, E.,
Loh, L., Mason, R.D., Wilson, C.M., Law, M.G., Handley, A.J., Kent, S.J., 2008. Control of
viremia following immunotherapy of SIV-infected macaques with peptide pulsed
blood. Plos Pathogens e12 4 (12), e 100055 (an online journal).
Fernandez, C.S., Stratov, I., De Rose, R., Walsh, K., Dale, C.J., Smith, M.Z., Agy, M.B., Hu,
S.L., Krebs, K., Watkins, D.I., O'Connor, D.H., Davenport, M.P., Kent, S.J., 2005.
Rapid viral escape at an immunodominant simian–human immunodeﬁciency
virus cytotoxic T-lymphocyte epitope exacts a dramatic ﬁtness cost. J. Virol. 79
(9), 5721–5731.
Fernandez, C.S., Smith, M.Z., Batten, C.J., De Rose, R., Reece, J.C., Rollman, E., Venturi, V.,
Davenport, M.P., Kent, S.J., 2007. Vaccine-induced T-cells control reversion of AIDS
virus immune escape mutants. J. Virol. 81 (8), 4137–4144.
Frahm, N., Kiepiela, P., Adams, S., Linde, C.H., Hewitt, H.S., Sango, K., Feeney, M.E., Addo,
M.M., Lichterfeld, M., Lahaie, M.P., Pae, E., Wurcel, A.G., Roach, T., St John, M.A.,
Altfeld, M., Marincola, F.M., Moore, C., Mallal, S., Carrington, M., Heckerman, D.,
Allen, T.M., Mullins, J.I., Korber, B.T., Goulder, P.J., Walker, B.D., Brander, C., 2006.
Control of human immunodeﬁciency virus replication by cytotoxic T lymphocytes
targeting subdominant epitopes. Nat. Immunol. 7 (2), 173–178.
Friedrich, T.C., Dodds, E.J., Yant, L.J., Vojnov, L., Rudersdorf, R., Cullen, C., Evans, D.T.,
Desrosiers, R.C., Mothe, B.R., Sidney, J., Sette, A., Kunstman, K., Wolinsky, S., Piatak,
M., Lifson, J., Hughes, A.L., Wilson, N., O'Connor, D.H., Watkins, D.I., 2004. Reversion
of CTL escape-variant immunodeﬁciency viruses in vivo. Nat. Med. 10 (3), 275–281.
Friedrich, T.C., Valentine, L.E., Yant, L.J., Rakasz, E.G., Piaskowski, S.M., Furlott, J.R.,
Weisgrau, K.L., Burwitz, B., May, G.E., Leon, E.J., Soma, T., Napoe, G., Capuano 3rd, S.
V., Wilson, N.A., Watkins, D.I., 2007. Subdominant CD8+ T-cell responses are
involved in durable control of AIDS virus replication. J. Virol. 81, 3465–3476.
Hel, Z., Venzon, D., Poudyal, M., Tsai, W.P., Giuliani, L., Woodward, R., Chougnet, C.,
Shearer, G., Altman, J.D., Watkins, D., Bischofberger, N., Abimiku, A., Markham, P.,
Tartaglia, J., Franchini, G., 2000. Viremia control following antiretroviral treatment
and therapeutic immunization during primary SIV251 infection of macaques. Nat.
Med. 6 (10), 1140–1146.
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E.,
Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., Bishop, K., van der Stok, M., Nair,
K., Khan, N., Crawford, H., Payne, R., Leslie, A., Prado, J., Prendergast, A., Frater, J.,
McCarthy, N., Brander, C., Learn, G.H., Nickle, D., Rousseau, C., Coovadia, H.,Mullins, J.
I., Heckerman, D., Walker, B.D., Goulder, P., 2007. CD8(+) T-cell responses to different
HIV proteins have discordant associations with viral load. Nat. Med. 13 (1), 46–53.
Leslie, A.J., Pfafferott, K.J., Chetty, P., Draenert, R., Addo, M.M., Feeney, M., Tang, Y.,
Holmes, E.C., Allen, T., Prado, J.G., Altfeld, M., Brander, C., Dixon, C., Ramduth, D.,
Jeena, P., Thomas, S.A., St John, A., Roach, T.A., Kupfer, B., Luzzi, G., Edwards, A.,
Taylor, G., Lyall, H., Tudor-Williams, G., Novelli, V., Martinez-Picado, J., Kiepiela, P.,
Walker, B.D., Goulder, P.J., 2004. HIV evolution: CTL escape mutation and reversion
after transmission. Nat. Med. 10 (3), 282–289.
Lisziewicz, J., Trocio, J., Xu, J., Whitman, L., Ryder, A., Bakare, N., Lewis, M.G., Wagner, W.,
Pistorio, A., Arya, S., Lori, F., 2005. Control of viral rebound through therapeutic
immunization with DermaVir. Aids 19 (1), 35–43.
Lori, F., Lewis, M.G., Xu, J., Varga, G., Zinn Jr., D.E., Crabbs, C., Wagner, W., Greenhouse, J.,
Silvera, P., Yalley-Ogunro, J., Tinelli, C., Lisziewicz, J., 2000. Control of SIV rebound
through structured treatment interruptions during early infection. Science 290
(5496), 1591–1593.
Masemola, A.M., Mashishi, T.N., Khoury, G., Bredell, H., Paximadis, M., Mathebula, T.,
Barkhan, D., Puren, A., Vardas, E., Colvin, M., Zijenah, L., Katzenstein, D., Musonda, R.,
Allen, S., Kumwenda, N., Taha, T., Gray, G., McIntyre, J., Karim, S.A., Sheppard, H.W.,
Gray, C.M., 2004. Novel and promiscuous CTL epitopes in conserved regions of Gag
targeted by individuals with early subtype C HIV type 1 infection from southern
Africa. J. Immunol. 173 (7), 4607–4617.
Pal, R., Venzon, D., Letvin, N.L., Santra, S., Monteﬁori, D.C., Miller, N.R., Tryniszewska, E.,
Lewis, M.G., VanCott, T.C., Hirsch, V., Woodward, R., Gibson, A., Grace, M., Dobratz,
27Rapid CommunicationE., Markham, P.D., Hel, Z., Nacsa, J., Klein, M., Tartaglia, J., Franchini, G., 2002. ALVAC–
SIV–gag–pol–env-based vaccination and macaque major histocompatibility com-
plex class I (A⁎01) delay simian immunodeﬁciency virus SIVmac-induced
immunodeﬁciency. J. Virol. 76 (1), 292–302.
Peut, V., Kent, S.J., 2007. Utility of human immunodeﬁciency virus type 1 envelope as a
T-cell immunogen. J. Virol. 81 (23), 13125–13134.
Polacino, P.S., Stallard, V., Klaniecki, J.E., Pennathur, S., Monteﬁori, D.C., Langlois, A.J.,
Richardson, B.A., Morton, W.R., Benveniste, R.E., Hu, S.L., 1999. Role of immune
responses against the envelope and the core antigens of simian immunodeﬁciency
virus SIVmne in protection against homologous cloned and uncloned virus
challenge in macaques. J. Virol. 73 (10), 8201–8215.
Pratt, B.F., O'Connor, D.H., Lafont, B.A., Mankowski, J.L., Fernandez, C.S., Triastuti, R.,
Brooks, A.G., Kent, S.J., Smith, M.Z., 2006. MHC class I allele frequencies in pigtail
macaques of diverse origin. Immunogenetics 58 (12), 995–1001.
Sacha, J.B., Chung, C., Rakasz, E.G., Spencer, S.P., Jonas, A.K., Bean, A.T., Lee,W., Burwitz, B.
J., Stephany, J.J., Loffredo, J.T., Allison, D.B., Adnan, S., Hoji, A., Wilson, N.A., Friedrich,
T.C., Lifson, J.D., Yang, O.O., Watkins, D.I., 2007. Gag-speciﬁc CD8+ T lymphocytes
recognize infected cells before AIDS-virus integration and viral protein expression.
J. Immunol. 178 (5), 2746–2754.Shen, A., Zink, M.C., Mankowski, J.L., Chadwick, K., Margolick, J.B., Carruth, L.M., Li, M.,
Clements, J.E., Siliciano, R.F., 2003. Resting CD4+ T lymphocytes but not thymocytes
provide a latent viral reservoir in a simian immunodeﬁciency virus — Macaca
nemestrina model of human immunodeﬁciency virus type 1-infected patients on
highly active antiretroviral therapy. J. Virol. 77 (8), 4938–4949.
Smith, M.Z., Dale, C.J., De Rose, R., Stratov, I., Fernandez, C.S., Brooks, A.G.,
Weinfurter, J.T., Krebs, K., Riek, C., Watkins, D.I., O'Connor, D.H., Kent, S.J.,
2005a. Analysis of pigtail macaque major histocompatibility complex class I
molecules presenting immunodominant simian immunodeﬁciency virus epi-
topes. J. Virol. 79, 684–695.
Smith, M.Z., Fernandez, C.S., Chung, A., Dale, C.J., De Rose, R., Lin, J., Brooks, A.G., Krebs, K.
C., Watkins, D.I., O'Connor, D.H., Davenport, M.P., Kent, S.J., 2005b. The pigtail
macaque MHC class I allele Mane-A⁎10 presents an immundominant SIV Gag
epitope: identiﬁcation, tetramer development and implications of immune escape
and reversion. J. Med. Primatol. 34 (5–6), 282–293.
Villinger, F., Brice, G.T., Mayne, A.E., Bostik, P., Mori, K., June, C.H., Ansari, A.A., 2002.
Adoptive transfer of simian immunodeﬁciency virus (SIV) naive autologous CD4(+)
cells to macaques chronically infected with SIV is sufﬁcient to induce long-term
nonprogressor status. Blood 99 (2), 590–599.
